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Intervening with Urinary Tract Infections Using AntiAdhesives Based on the Crystal Structure of the FimH–
Oligomannose-3 Complex
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Abstract
Background: Escherichia coli strains adhere to the normally sterile human uroepithelium using type 1 pili, that are long,
hairy surface organelles exposing a mannose-binding FimH adhesin at the tip. A small percentage of adhered bacteria can
successfully invade bladder cells, presumably via pathways mediated by the high-mannosylated uroplakin-Ia and a3b1
integrins found throughout the uroepithelium. Invaded bacteria replicate and mature into dense, biofilm-like inclusions in
preparation of fluxing and of infection of neighbouring cells, being the major cause of the troublesome recurrent urinary
tract infections.
Methodology/Principal Findings: We demonstrate that a-D-mannose based inhibitors of FimH not only block bacterial
adhesion on uroepithelial cells but also antagonize invasion and biofilm formation. Heptyl a-D-mannose prevents binding of
type 1-piliated E. coli to the human bladder cell line 5637 and reduces both adhesion and invasion of the UTI89 cystitis
isolate instilled in mouse bladder via catheterization. Heptyl a-D-mannose also specifically inhibited biofilm formation at
micromolar concentrations. The structural basis of the great inhibitory potential of alkyl and aryl a-D-mannosides was
elucidated in the crystal structure of the FimH receptor-binding domain in complex with oligomannose-3. FimH interacts
with Mana1,3Manb1,4GlcNAcb1,4GlcNAc in an extended binding site. The interactions along the a1,3 glycosidic bond and
the first b1,4 linkage to the chitobiose unit are conserved with those of FimH with butyl a-D-mannose. The strong stacking
of the central mannose with the aromatic ring of Tyr48 is congruent with the high affinity found for synthetic inhibitors in
which this mannose is substituted for by an aromatic group.
Conclusions/Significance: The potential of ligand-based design of antagonists of urinary tract infections is ruled by the
structural mimicry of natural epitopes and extends into blocking of bacterial invasion, intracellular growth and capacity to
fluxing and of recurrence of the infection.
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immune system in a Toll-like receptor 4-dependent manner [3].
This induces the secretion of cytokines by the urothelial cells and
recruitment of neutrophils to the mucosal surfaces for the
elimination of the bacteria [4]. A subpopulation of UPEC escapes
this eradication mechanism of the host by invading into the large
superficial epithelial cells in a type 1 pili-dependent mechanism
[5,6]. However, hosts with a robust and timely innate immune
response manage to get rid of this bacterial intracellular nesting by
exfoliation of the large, superficial umbrella cells and discharge of
these infected cells with the urine [7,8].

Introduction
Pili and fimbriae on the bacterial cell are virulence factors that
mediate adhesion of pathogenic bacteria to host cell receptors [1].
Urinary tract infections (UTIs) in humans are frequently caused by
uropathogenic Escherichia coli (UPEC) expressing type 1 pili. The
FimH adhesin at the tip of type 1 pili recognizes terminal mannose
units of uroplakin Ia (UPIa), a membrane glycoprotein that is
abundantly expressed on superficial epithelial umbrella cells of the
urinary tract [2]. Bacterial attachment stimulates the innate host
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at the non-reducing end of the D1 arm of high-mannose glycans
[26]. Mannotriose and mannopentaose do not exhibit a
significantly higher affinity than their linear moiety Mana1,3Man
(Kd,200 nM). Conversely, oligomannose-3 and oligomannose-5,
carrying the b1,4-linked chitobiose as an anchor to an asparagine
in the Asn-X-Ser/Thr motif of N-linked glycoproteins, have
another 10-fold increase in affinity for the FimH RBD (Kd,20
nM) over Mana1,3Man [26].
Regardless of the well-characterized fine-specificity of FimH,
FimH variant strains have also been categorized into those with a
high affinity for D-mannose, predominantly represented by
UPECs, versus fecal, commensal E. coli strains that only displayed
an intermediate affinity for mannotriose (Mana1,6(Mana1,3)Man) [27]. These different bacterial binding characteristics under
static binding conditions had been attributed to variation in the
FimH RBD. Nonetheless, the isolated RBDs of all FimH variants,
except for the enterohaemoraghic isolates carrying the
Asn135Lys mutation in their pocket, do not differ in their
affinities for high-mannose glycans [26,28]. Isolated RBDs or
fimbrial tip adhesin that are out of the context of their own
fimbriae have recently been suggested to always occur in a highaffinity conformation [29]. On the other hand, when present
within their endogenous pilus, the adhesin can undergo a
transition to the high-affinity conformation under shear force
enhanced adhesion, and it is this phenomenom where amino acid
variation in FimH can give rise to ten-fold differences in bacterial
adhesion. Shear enhanced bacterial adhesion was most pronounced to layers coated with the weakly binding mannose than
to a surface coated with the more specific mannotriose and
involved a minimum of shear for the fecal FimH variant E. coli
F18 strain [30]. However, no such shear threshold was observed
for type 1-piliated E. coli binding to mannotriose or for a Ppiliated pyelonephritis strain binding to Gala1,4Gal [31]. Thus
changes in the receptor structure, that affect the fine-specificity of
FimH, can more dramatically than FimH variation impact on the
colonization behaviour of type 1-piliated bacteria under flow
conditions. In this context, the relevance of a shear threshold
observed for single-exposed mannose is feeble given that
mannose, recognized by FimH at the termini of naturally
occurring glycans, is almost invariably involved in a glycosidic
linkage.
FimH has been reported to bind to several glycosylationdependent receptors in the urinary tract, among which are
uroplakin Ia (UPIa) [2], Tamm-Horsfall glycoprotein (THP) [32]
and very recently b1 and a3 integrins [33]. Many pathogens gain
entry into target host cells by binding integrins either directly or
indirectly via the recognition of extracellular matrix proteins. UPIa
is an integral membrane protein of the large superficial epithelial
cells of the bladder located as a FimH receptor on the six inner
domains of the uroepithelial plaque particle [34]. It belongs to the
superfamily of tetraspanins [35] that are often found to complex
with b1 integrin receptors [36]. Mouse UPIa4 presents highmannose glycans on Asn169 with a heterogeneity ranging from
Man6GlcNAc2 to Man9GlcNAc2 [37]. The same high-mannose
type glycans decorate b1 and a3 integrins [38]. None of these
structures expose Mana1,3Manb1,4GlcNAc, terminally at the
non-reducing end of the glycan branch. Perhaps this is not so
striking, as glycoproteins bearing Man5GlcNAc2 glycans are
degraded preferentially [39]. The only isomer of oligomannose-6
encountered so far on uroplakins covers Mana1,3Manb1,4GlcNAc with an extra a1,2-linked D-mannose [37], thus masking the
epitope with high affinity for FimH [40]. THP is secreted in the
urine as a natural inhibitor of type 1-mediated bacterial adhesion
through its high-mannosylated Asn251 residue [41].

Bacteria within the cytosol of umbrella cells replicate and within
hours develop into tightly packed, biofilm-like intracellular
bacterial communities (IBCs) [9]. Upon maturation of the IBCs,
the bacteria disperse from the IBCs and re-emerge in the bladder
lumen in long, filamentous shapes that helps them to evade
neutrophil phagocytosis [10,11]. They can then reinvade neighbouring epithelial cells to re-establish infection. As such, even after
the acute infection is resolved, bacteria can remain within the
bladder for many days to weeks, regardless of standard antibiotic
treatments, and can be implicated in recurrent urinary tract
infection (rUTI) [12–14]. Most UPEC isolates from women with
acute or rUTIs, asymptomatic bacteriuria and pyelonepritis
replicate in IBCs in C3H/HeN mice, although IBCs from isolates
associated with acute UTIs remained significantly smaller [15].
UPEC that are unable to express type 1 pili are dramatically
attenuated in their virulence, refrain from intracellular aggregation
and maturation into an IBC and therefore fail to flux back out of
the cells [16].
A different, intracellular path of the bacteria is commenced
through the endocytosis in the fusiform or discoidal vesicles of
superficial umbrella cells [17]. The bacteria make use of the vesicle
trafficking in the umbrella cells to escape elimination during
voiding. Endocytosis in the umbrella cells is coupled to exocytosis
of secretory lysosomes [18]. Exocytosis helps to enlarge the apical
membrane during bladder filling under hydrostatic pressure. High
intracellular cAMP and calcium levels enhance exocytosis of the
UPECs back into the lumen of the bladder [17]. It is unclear
whether the bacteria are fit enough following their stay in the
umbrella cell lysosomes to start another invasive cycle [19]. The
uroepithelial cell layer underlying the umbrella cells can also be
subject to invading bacteria, possibly upon the incomplete
elimination of type 1 piliated E. coli during exfoliation of the
superficial, highly differentiated umbrella cells [8]. In those
immature cells, the bacteria do not reside in the cytosol but
rather are sequestered in late endosomes or lysosomes where they
remain in a non-replicating state [20]. Those quiescent intracellular reservoirs (QIRs) persist for months even in the face of
antibiotics and the host defense, that mainly attack growing
bacteria [8,12,13]. Only upon differentiation of the immature host
cells and rearrangement of the cytoskeleton that tends to inhibit
the intracellular replication, the QIRs resolve to develop
intracellular inclusions similar to experimental IBCs [20]. Host
cytokeratin intermediate filaments are closely associated with and
probably help with biofilm formation within these pod-shaped
inclusions [20].
The attachment of adhesins on the bacterial cell surface to
definite carbohydrates on the host tissue surface is considered to be
an initial and critical step in pathogenesis. Antibodies that
specifically block the binding of FimH to its natural receptor also
prevent infection [21]. Revealing the interaction between FimH
and its structural receptor would allow the design of carbohydratebased anti-adhesives [22]. The preference of the fimbrial adhesin
for structures found in mannosylated N-linked glycan chains on
eukaryotic cell glycoproteins suggested that these structures would
serve as the receptors for type 1-piliated E. coli strains [23,24]. The
group of Sharon described in the early eighties the strong
inhibitory potency of Mana1,3Manb1,4GlcNAc on the agglutination of red blood cells and yeast cells and suggested that this
trisaccharide would best fit the FimH binding pocket [25]. More
recently, equilibrium dissociation constants (Kd) derived from
surface plasmon resonance (SPR) solution affinity measurements
or from the displacement of tritiated mannose from the receptorbinding domain (RBD) of FimH, consistently approved the strong
preference of FimH for oligomannosides exposing Mana1,3Man
PLoS ONE | www.plosone.org
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Man3. It also indicated that the presence of the b-linkage alone
is not sufficient to explain the more significant increase in
affinity between on the one hand mannotriose or mannopentaose, and on the other hand oligomannose-3 and oligomannose-5 [26]. Thus the chitobiose unit that bridges the mannosides to the asparagine in the Asn-X-Ser/Thr motif of the
glycoprotein receptor contributes more significantly to the
interaction with FimH.

UTIs are one of the most prevalent infections for humans.
Almost half of all women will experience at least one UTI in
their lifetime. More problematic is the evolution of acute UTIs
into chronic infections, with recurrence of the symptoms two or
more times within months of a primary infection [42].
Modifications in the glycosylation of FimH receptor proteins
on eukaryotic cells may alter the host sensitivity to UTI causing
strains. For example, diabetic patients and elderly women show
increased bladder cell binding by FimH [43] and this is further
correlated with an increased frequency of asymptomatic
bacteriuria [44]. Free Mana1,3Manb1,4GlcNAc oligosaccharide can be isolated in abnormally high amounts from urine of
patients with mannosidosis [45]. For mannosidosis patients the
abundance of this high-affinity FimH epitope in the urine may
act as a natural inhibitor for urinary tract infections, although a
decreased risk of UTIs in patients with a-mannosidase
deficiency has not been described. The high frequency of
recurrent infections and the increasing antibiotic resistances of
UPECs [46] highlight the need for alternative treatments using
carbohydrate-derived molecules as potential anti-adhesives.
Their non-bactericidal effect makes the selection of strains
resistant to such agents much more unlikely than those resistant
to antibiotics [22].
Biochemical and docking studies predicted that the enhanced
binding of Mana1,3Manb1,4GlcNAc is accomplished by interactions
of the central mannose and GlcNAc in the tyrosine gate extending
from the FimH mannose-binding pocket [26,47]. To gain insight into
the selectivity of FimH for this trisaccharide epitope, we cocrystallized FimH with the trisaccharide-presenting oligomannose-3
and investigated the importance of the glycosidic linkage of
Mana1,3Man with N-acetyl glucosamine (GlcNAc) of the chitobiose
unit of N-linked glycans. The FimH RBD shows high affinities for
alkyl a-D-mannosides, with affinities up to a Kd of 5 nM for heptyl aD-mannose (HM) [47]. We set out to explore the inhibitory capacity
of HM for lower UTIs caused by type 1-piliated UPECs in mice. We
find that alkyl a-D-mannosides and other synthetic inhibitors of FimH
confirm binding properties of the high-mannose epitope. The alkyl
chain of butyl a-D-mannose, bound to FimH in two previously
determined co-crystal structures, follows the trail of the a1,3 linkage
to the central mannose and the first b1,4 glycosidic linkage to the
chitobiose. The potential of ligand-based design of antagonists of
UTIs appears to be ruled by structural mimicry of specific spots on
mannosylated receptors. This anti-adhesive ability extends into
blocking of bacterial invasion, intracellular growth and capacity to
fluxing and recurrence of the infection.

Crystal structure of the FimH receptor-binding domain in
complex with oligomannose-3
Oligomannose-3 has been crystallized in complex with the
FimH RBD. This oligosaccharide exposes the substructure
Mana1,3Manb1,4GlcNAc terminally on its D1 branch (Figure 1).
Therefore it is ideally suited to reveal the structural basis of its
high-affinity interaction with FimH. Initial crystals have been
grown by equilibration through vapor diffusion and the crystallization condition was optimized through the addition of 3%
glycerol (Figure S1) .
The solution of the molecular replacement contains two
FimH RBDs per asymmetric unit in the P3121 space group
(Figure 2, Table S1). Upon the first atomic refinement a clearly
interpretable electron density for Mana1,3Manb1,4GlcNAc was
visible, equally well in both RBDs. Refinement against the
crystallographic data with a 2.1 Å high-resolution cut-off led to
good protein geometry and oligosaccharide conformation
determination. The root mean square deviation between the
two RBDs is 0.56 Å for all main chain atoms. The torsion angles
of the Manb1,4GlcNAc and Mana1,3Man glycosidic bonds in
oligomannose-3 resemble within a few degrees to those observed
in the crystal structure of the Mana1,3Manb1,4GlcNAc
trisaccharide [48]. Although the y torsion angle of Mana1,3Man deviates from the average minimum energy modelled for
these glycans for all distinct conformers of glycosidic linkages
found in either N- or O-linked glycans [49], it falls well within
the range of allowed minimum energy conformations for w and
y glycosidic torsion angles [50].
Oligomannose-3 conforms into a relatively planar structure that
inserts almost like a sheet into the tyrosine gate (Figures 2 and 3A),
with an angle at both ends. The same extensive hydrogen bonding,
hydrophobic contacts and van der Waals interactions are achieved
by binding of oligomannose-3 in both FimH RBDs of the crystal
structure (Figure 2). The solvent accessible surface area buried
through the binding of oligomannose-3 leads to a reduction of

Results
The chitobiose anchor to Asn-glycosylated FimH
receptors is important for specificity
Previous epitope mapping on high-mannose glycan receptors
revealed the highest affinity of the FimH RBD for oligomannose-3 and oligomannose-5 [26]. Both these oligomannosides
expose Mana1,3Manb1,4GlcNAc at the non-reducing end of
the D1 branch and have an increased affinity for FimH over
mannotriose and mannopentaose that lack the chitobiose unit
(Figure 1). The increased affinity was thought to be due partially
to the b-anomeric linkage to the chitobiose GlcNAcb1,4GlcNAc. The binding constants of the FimH RBD from the J96
cystitis strain for Mana1,3ManbOMe and for the anomeric
mixture of Mana1,3Man have been determined using SPR, to
investigate the contribution of the glycosidic linkage. This
resulted in affinities of Kd = 112 nM and 281 nM respectively,
showing that FimH selects out the b-anomeric configuration on
PLoS ONE | www.plosone.org

Figure 1. Oligomannose-3 as part of the high-mannose
glycans. Oligomannose-9 (Kd,420 nM) is the full structure here
displayed. Oligomannose-3 (blue, Kd,20 nM) is the substructure that
was crystallized in complex with the FimH adhesin. It interacts with
FimH as an extended tetrasaccharide, underlined with a red hatched
line. Oligomannose-5 (Kd,12 nM) includes an extra mannotriose core
over oligomannose-3 through addition of ManA and ManB (fuchsia).
Mannopentaose (Kd,120 nM) and mannotriose (Kd,200 nM) are
boxed in fuchsia and blue frames respectively.
doi:10.1371/journal.pone.0002040.g001
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Ile13 of a symmetry-related RBD with Man4’ bound to the
second RBD (forest-green molecule in Figure 2) stabilize some
of these waters, whereas Man4’ bound to the first RBD is fully
solvent exposed.
For the first time in a FimH structure [47,52,53], a nickel ion
was observed, interlinked with the mannose binding pocket by
Asp47 (Figure 2). The nickel ion is ligated in an octahedral setting
by the carboxylate group of Asp47, the imidazole group of His45
and four water molecules. Also unseen before in any FimH
structure are two sulphate ions in a highly charged interface in the
crystal packing (Figure 2).
The non-reducing end Man4 of oligomannose-3 (Figure 1) is
attracted to the deep, monomannose-binding polar pocket
(Figure 3A, red) through a hydrophobic tyrosine gate (Figure 3A,
blue) to make previously well-defined interactions [47,53]. Eleven
hydrogen bonds are formed between the Man4 and the FimH
residues Phe1, Asn46, Asp47, Asp54, Gln133, Asn135 and Asp140
(Figure 4). A water molecule interacting with O2 of Man4 is a
strongly conserved feature in the mannose binding pocket. The
apolar B-face of Man4 provides interaction with Ile13 and
Phe142, and its C5-C6 bond interacts with Ile52. Residues
Tyr48, Ile52 and Tyr137 of the tyrosine gate are involved in
several aromatic/hydrophobic and van der Waals contacts with
oligomannose-3, thus stabilizing the glycan-lectin complex
(Figures 3 and 4). Man3 hooks over the side chain of Ile52 while
stacking its apolar B-face onto the Tyr48 aromatic side chain
(Figures 3A–C). A close apolar contact is achieved between C5 of
GlcNAc2 and Tyr137. The C6-O6 bond of GlcNAc2 fares well in
a hydrophobic environment created by Tyr48 and Ile52 (Figure 4).
This could help to orient the strong (2.7 Å) hydrogen bond of the
O6 hydroxyl on GlcNAc2 directly towards the hydroxyl of the
Thr51 side chain (Figure 3D). This latter threonine interacts
hydrophobically with the C7–C8 bond of the acetyl group of the
reducing end GlcNAc1. GlcNAc1 intramolecular hydrogen bonds
with GlcNAc2 and its N-acetyl group makes a van der Waals
contact with the methyl group of the Thr51 side chain (Figure 3D).
It can be seen that glycosidic linkage of GlcNAc1 via O1 to a
glycoprotein would pull FimH very close to its receptor upon
binding (Figure 3D).

Figure 2. Crystal structure of FimH in complex with oligomannose-3. The two FimH RBDs related by non-crystallographic symmetry
(green and forest-green, Ig-fold labeling) both bind oligomannose-3
(only one is shown in blue cyan), interconnected via Asp47 to a nickel
ion (green cyan). His45 and Asp47 and four waters ligate the nickel ion
in an octahedral configuration. Sulphate ions (yellow with red oxygens)
stabilize a highly charged crystal packing interface by bridging Val112
and Ser113 with Arg132 from the two crystallographically independent
RBDs with Arg92 and Tyr55 from a symmetry-related RBD.
doi:10.1371/journal.pone.0002040.g002

Parallels between the binding of oligomannose-3 and
alkyl a-D-mannosides with FimH
Butyl a-D-mannose is a high-affinity ligand for FimH
(Kd = 150 nM) that was found serendipitously in two previous
FimH crystal structures [47]. We compared the interaction
interfaces between FimH and oligomannose-3 with those between
FimH and butyl a-D-mannose. Superposing the mannose of the
butyl a-D-mannosides onto Man4 of oligomannose-3 and
application of the transformation matrix to the whole molecules
showed that the butyl chain follows the hydrophobic trail through
the tyrosine gate by the Mana1,3Man and Manb1,4GlcNAc
linkages (Figure 5A). In contrast to the stable position of the
mannose bound in the monosaccharide-binding pocket, the
temperature factors of the ligand atoms gradually increase beyond
the a1,3 position, both for oligomannose-3 and for butyl a-Dmannose.
The side of oligomannose-3 that is not embraced by the tyrosine
gate displays hydration of the exocyclic glycosidic oxygens
(Figures 4 and 5A) that is maintained between oligomannose-3
and butyl a-D-mannose. The hydration on the a-anomeric oxygen
of the mannose bound into the polar pocket is conserved, as well as
its hydrogen bonding network with Asn138 and Asp140 (Figure 5B)
that are residues in the loop connecting b-strands F and G
(Figure 3). Also a water molecule hydrogen bonding to the

solvent accessible surface area of 312.161.3 Å2 for oligomannose3 and 462.266,6 Å2 for FimH both, using the CCP4 program
NACCESS. Between the two crystallographically-independent
FimH RBDs 537.566.75 Å2 is excluded from the solvent. This
agrees well with the average areas excluded from the solvent by
pairwise interactions (388.163 Å2 between FimH and oligomannose-3 and 534 Å2 between the two FimH RBDs) calculated by
MSDpisa version v1.14 [51].
The non-reducing end Man4 anchors into the mannosebinding pocket, whereas the reducing end GlcNAc1 folds over
Thr51. Very specific interactions with the tyrosine gate occur in
the mannose-binding pocket itself and all along Mana1,3Manb1,4GlcNAc via the a1,3 and the first b1,4 glycosidic
linkages. FimH is not directly recognizing the second nonreducing end mannose, Man4’ (Figure 3). Man4’ and GlcNAc1,
the two saccharides that exit from the receptor-binding site,
display a larger flexibility in an extensively hydrated environment, resulting in less-well defined electron density and higher
temperature factors. Crystal packing contacts with Phe142 and
PLoS ONE | www.plosone.org
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Figure 3. Panel of FimH lectin domain interactions along the oligomannose-3 chain. A, Electron density map, contoured at 1 e/Å3, for
oligomannose-3 in the FimH receptor-binding site. The surface of the binding site is subdivided into its hydrophobic support platform (grey, residues
Phe142, Phe1 and Ile13), its polar pocket (red, residues Asn46, Asp47, Asp54, Gln133, Asn135, Asn138 and Asp140), the tyrosine gate (blue, residues
Tyr137, Ile52 and Tyr48) and residue Thr51 (green). B, Aromatic-to-saccharide stacking (green dashed lines) of the Tyr48 side chain onto the B-face of
Man3. C, van der Waals support of the b1,4 linkage (yellow dashed lines) and an hydrophobic contact of C5 of GlcNAc2 by Tyr137 (green dashed
lines). D, Thr51 tops of the site by hydrophilic (red), hydrophobic and van der Waals (yellow) interactions with the chitobiose. The anomeric O1 of
GlcNAc1 would be exchanged for by the nitrogen of the amide of aspargine on a receptor glycoprotein for FimH.
doi:10.1371/journal.pone.0002040.g003

exocyclic glycosidic oxygen linking Man3 to GlcNAc2 is
maintained (Figures 5 and 6B). It appears that synthetic
inhibitors strive for the best mimic of the interactions of FimH
with its natural receptor. Previous solution affinity measurements indicated that heptyl a-D-mannose is the best-binding
alkyl a-D-mannoside (Kd = 5 nM) [47]. A simulation in which
the butyl chain of butyl a-D-mannose was elongated to a heptyl
allowed a conformation in which the elongated tail follows
GlcNAc2 further along C4-C5-C6, expecting to form the
important interactions with Thr51, Ile52 and Tyr48. The
anti-adhesive proficiency with heptyl a-D-mannose was subsequently tested both on the human bladder cell line 5637 and in
C3H/HeN mice.
PLoS ONE | www.plosone.org

Mannose and heptyl a-D-mannose inhibit in vitro
adhesion of type 1-piliated E. coli
Type 1 pili-expressing AAEC185(pUT2002)(pMMB66) E. coli
cells at 106 cfu/ml were supplemented with a ten-fold dilution
series of D-mannose (Man) or heptyl a-D-mannose (HM) and
incubated for adhesion on bladder cell line 5637. Increasing
concentrations of Man or HM caused a significant reduction to
complete inhibition of bacterial bladder cell binding (Figure 6).
Adhesion could be completely inhibited by the addition of
100 mM Man to the bacterial inoculum, or by a 100-fold lower
concentration of HM. No inhibition was obtained with 100 mM
Man, whereas 1 mM of HM still had some inhibitory effect.
Similar data have been obtained with an inoculum of 107 cfu/ml.
5
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Figure 4. Scheme of the interactions in the extended FimH receptor-binding pocket. A network of hydrogen bonds (green dashed lines)
surrounds Man4. Further along oligomannose-3, only water molecules make hydrogen bonds along one side of oligomannose-3 except for the Thr51
side chain. The residues of the tyrosine gate, Tyr48, Ile52 and Tyr137, interact via aromatic stackings, hydrophobic and van der Waals contacts (all
marked in red) mainly with Man3 and GlcNAc2.
doi:10.1371/journal.pone.0002040.g004

Figure 5. Specificity spots for interaction with FimH. A, Superposing the FimH RBDs with the oligomannose-3 ligand (yellow, PDB entry 2vco,
2.1 Å resolution), with butyl a-D-mannose (magenta, 1uwf, 1.7 Å resolution) and with butyl a-D-mannose (cyan, 1tr7, 2.1 Å resolution). Tyr48 in the
1uwf structure (magenta) adopts a different side chain conformation, for the reason to avoid clashes in the crystal packing. The butyl tail takes on a
conformation that matches the C3-C2-C1 greasy trace of the central Man3 almost precisely. B, Water positions in the crystal structures of the FimH
RBD (green) in complex with the oligomannose-3 ligand (yellow, waters in red and hydrogen bonds in blue dashed lines) match those of the FimH
RBDs of the butyl a-D-mannose-liganded structures (waters in magenta for 1uwf, waters in cyan for 1tr7).
doi:10.1371/journal.pone.0002040.g005
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Figure 6. Inhibition of bacterial adhesion to 5637 bladder cells by mannose or heptyl a-D-mannose. Type 1 pili-expressing E. coli were
incubated at 106 cfu/ml (FimHpos) with the bladder cells, or had been mixed with a ten-fold dilution series of Man or HM prior to incubation, to
compare inhibition of bacterial binding by the two sugars. An isogenic fimH-negative strain served as a negative control (FimHneg).
doi:10.1371/journal.pone.0002040.g006

intracellular. Mice were infected with UTI89 in PBS or in a MM
or HM solution. At 1 hour post-infection, the luminal and
intracellular bacterial loads were assessed. There was a significant
decrease in the number of luminal bacteria bound to the

These results suggest that HM is more efficient at reducing FimHmediated bacterial adherence, in accordance with its higher
affinity for FimH.

Heptyl a-D-mannose reduces bacterial levels in a murine
cystitis model
Extensive research has shown that type 1 pili and their adhesin,
FimH, are essential for binding and invasion in the murine cystitis
model [6,33,53]. It was hypothesized that blocking of the FimH
binding pocket by preferential binding to a soluble mannose
residue would reduce the binding to uroplakins on the epithelial
cell surface of the bladder. This loss of binding would result in less
invasion and ultimately a reduced infection. To test this
hypothesis, bacteria were incubated in the presence of a derivative
of mannose prior to inoculation into mouse bladders. Introductory
to this experiment, the intrinsic toxicity of HM was assessed in
Female BALB/c mice. HM was administered at 50 mM
concentration through a catheter (50 ml), intranasal (20 ml) and
intravenously (150 ml) to three mice each, but no acute toxicity has
been observed. At 6 hours post-infection, the bacteria present
within the bladder were enumerated. Wild-type UTI89 incubated
with PBS alone had a mean level of infection of ,36105 cfu/mL
(Figure 7). Incubation of UTI89 with 0.5 mM of HM showed no
significant decrease in infection. However, at a concentration of
5 mM HM, there was a significant decrease in infection at 6 hours
post-infection (p#0.0001). Methyl a-D-mannose (MM) gave no
decrease in bacterial numbers at the same concentration. A
significant decrease in bacterial burden was only observed when
increasing the concentration of MM to 1M (data not shown), a 200
fold higher concentration then the one sufficient for HM. The
tighter binding of HM to FimH, as compared to MM, could
explain this difference. These results suggest that by inhibiting the
ability of FimH to bind to mannosylated uroplakins, the bacterial
infection can be prevented.

Figure 7. Bacterial load in the mouse bladder 6 hours postinfection. Mice were inoculated with UTI89, either untreated or treated
with MM or HM. At 6 hours post-infection there was a significant
decrease in the amount of bacteria treated with 5 mM HM in the
bladder (p#0.0001 by Mann Whitney test). This same decrease was not
observed with bacteria treated with 5 mM MM. Bacteria treated with
0.5 mM HM were not significantly reduced relative to the untreated
infection.
doi:10.1371/journal.pone.0002040.g007

Heptyl a-D-mannose reduces intracellular bacterial levels
Since there is a reduction in the amount of bacteria present in
the bladder at 6 hours post-infection with HM incubation
(Figure 7), we wanted to assess the amount of bacteria that went
PLoS ONE | www.plosone.org
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uroepithelium when treated with 5 mM and 0.5 mM HM
(p#0.01) (Figure 8). This same decrease was not seen when using
5 mM MM. Relative to untreated UTI89, UTI89 incubated with
5 mM HM had a significant decrease in intracellular population
(p#0.01). There was no significant decrease in invaded bacteria
treated with 5 mM MM or 0.5 mM HM. These data indicate that
HM is interfering not only with type 1 pili-mediated bacterial
binding but also with type 1 pili-dependent invasion of UPEC.

Heptyl a-D-mannose inhibits biofilm formation in vitro
The development and maturation of IBCs into communities
with biofilm-like properties has been shown recently to depend on
type 1 pili [16]. We speculated that blocking the FimH binding
pocket on type 1 pili would inhibit biofilm formation by inhibiting
the adhesive properties of the pili. Bacterial biofilms were grown in
the presence of varying concentrations of either HM or MM to
elucidate their biofilm inhibiting properties (Figure 9). Biofilm of
UTI89 E. coli was significantly reduced (p,0.01) only at the
highest concentration of MM, 1 mM. However, in the presence of
HM, there was a significant decrease in biofilm formation at
10 mM (p,0.001) and both 1 mM and 100 mM concentrations
(p,0.0001). This suggests that blocking of the type 1 pili FimH
adhesion with HM inhibits biofilm formation. Interestingly, at the
lowest concentration of HM (1 mM) there was a significant
increase in biofilm formation (p,0.001). A low concentration of a
weak inhibitor appears to allow the bacteria to organize into a
better matrix through their type 1 pili [54].

Figure 9. Biofilm formation in the presence of methyl or heptyl
a-D-mannose. Standard biofilm assays showed a great reduction of
UTI89 biofilm formation in the presence of 100 mM and 1 mM HM
(p,0.0001) and a significant increase (p,0.01) in the presence of 1 mM
MM.
doi:10.1371/journal.pone.0002040.g009

bacteria can invade the cells and rapidly replicate into intracellular
bacterial communities, named IBCs, which mature into tightly
packed biofilm-like societies [15,16]. As the infection proceeds, the
bacteria filament and flux out of the cells [7,11]. They can then
reinvade neighbouring cells to re-establish infection [14]. Inhibition of UPEC binding to bladder cells will potentially inhibit
invasion and limit the bacteria’s ability to build up formidable
numbers within the bladder. A competitive sugar could potentially
disrupt the IBC pathway.
Blocking bacterial invasion could reduce the infection and
decrease recurrences. It had been demonstrated already from very
early on by Sharon’s group that mannose has an inhibitory can
inhibit FimH-mediated bacterial adhesion [55]. We looked into
the ability of heptyl a-D-mannose (HM) to reduce infection,
because HM has an optimized alkyl length for interaction with
FimH [47]. Inhibition by soluble mannose (Man) or methyl a-Dmannose (MM) or HM of bacterial adhesion to the bladder cel line
in vitro or upon transurethral catheterization into the mouse
bladder indicates that the bacteria cannot switch between HM and
the mannosylated uroplakins. Once HM is bound to FimH on the
type 1 pili, the bacteria are irreversibly inhibited in their binding to
the bladder surface and the infection is reduced. However, the
weak inhibitor MM has a relatively high efficiency in the bladder
binding assay that is not in direct correlation with its affinity
compared to HM. The affinity of MM for FimH is 500-times less
than this of HM, but a concentration of MM a 100-fold higher
than the inhibitory concentration of HM is sufficient. The
explanation may be in the fact that the in vitro adhesion assay is
being performed under shaking conditions. Nilsson studied the
inhibitory effect of MM on binding of type 1-piliated E. coli to
mannosylated surfaces under different shear stress conditions.
During rolling, FimH molecules transiently bind and detach from
surface receptors, allowing a weak soluble inhibitor such as MM to
eventually bind to all FimH molecules, thereby preventing further
adhesion [54,56]. In contrast, stationary adhesion is mediated by
long-lived adhesin-receptor bonds that prevent inhibitor binding
during the time course of the experiments (,10 min). HM forms
such high-affinity intractions with FimH, also under still

Discussion
Adhesion, invasion and the formation of intracellular
biofilms
UPEC express type 1 pili which bind to mannosylated residues
on the surface of epithelial bladder cells. Once bound, some

Figure 8. Gentamicin protection assay to determine luminal
versus intracellular bacterial population. Mice were inoculated
with UTI89 either untreated or treated with MM HM. At 1 hour postinfection, bladders were harvested and processed. Luminal bacteria
were obtained from washes of the bladder. The remaining extracellular
bacteria were killed with gentamicin and invaded, intracellular bacteria
were counted.
doi:10.1371/journal.pone.0002040.g008
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conditions. The data on the inhibition by MM or HM of adhesion
in the C3H/HeN mice indeed pledge that, for a free smallmolecule ligand to be an efficient FimH anti-adhesive even under
conditions of fluid flow, such as in the bladder, it must bind
significantly tighter to FimH than the binding of FimH to the
receptor molecules on the bladder cells, in order to overcome the
shear-enhanced affinity. HM corresponds to these requirements,
having an affinity for FimH higher than any known natural
mannosylated receptor. In this context it is interesting to note that
whereas human uroplakin UP1a and integrins only carry mannose
receptors with intermediate affinity for FimH, the abundantly
secreted urinary glycoprotein human THP displays 8% of the
high-affinity oligomannose-5 receptors and 75% of oligomannose6 exposing Mana1,3Man on the D2 branch (Figure 1) [57].
IBCs are biofilm-like groups of bacteria that form upon
adhesion, invasion and replication. Biofilm development requires
tight interactions between individual cells in the community.
Biofilm formation and maturation in UPEC IBCs is type 1-pili
dependent [16] and the homotypic interactions between E. coli by
means of type 1 pili are glycan dependent [58]. Therefore, the
ability to disrupt biofilm formation using MM or HM was
evaluated. A significant decrease in biofilm formation was
observed with as little as 10 mM HM, a 100-fold lower
concentration than was needed with MM. The only other data
that exist on the inhibition of biofilm formation by a glycan are the
inhibition of Gram-positive and Gram-negative biofilms by a
secreted group II capsule polysaccharide [59]. The concentrationdependent inhibition of biofilm formation by mannose glycans
indicates that the FimH adhesin is involved in biofilm formation
[58]. Another very interesting observation is the significant
increase in biofilm with very low concentrations of MM
(Figure 9). The presence of low concentrations of a soluble
inhibitor such as MM during a longer period of time (hours) under
conditions of low shear can sometimes help the bacteria to spread
further and thus colonize larger surfaces [54]. The absence of
shear and the presence of MM loosen the interactions between the
adhering bacteria and the surface, allowing them to (re-)organize
the biofilm. The extent to which the factors that are important for
biofilm formation on abiotic surfaces (our assay) are also applicable
for biofilm formation on biotic surfaces (e.g. in IBCs) needs to be
further studied. However the observation of bacterial biofilm
formation on abiotic surfaces is highly relevant in view of the use of
medical implants such as urinary catheters. The glycan-based
inhibition of UPEC biofilms is interesting in view of the thought
that glycoproteins abundantly secreted in the urine, such as THP,
could coat the catheter walls and serve as a glue for type 1-piliated
E. coli to initiate biofilm growth.
The IBCs, or the non-replicating bacteria in quiescent
intracellular reservoirs (QIRs), form a repository that can seed a
recurrent infection [12]. It was investigated whether the inhibition
of binding and biofilm formation in vitro could also reduce this
intracellular population during UTIs in a mouse model and thus
the likelihood of a recurrence. In the presence of 5 mM HM a
significant reduction in bacterial numbers in the bladders
occurred. Two-hundred times more MM was needed to obtain
the same effect. The results on inhibition with high concentrations
of mannose were less consistent, perhaps because FimH can still
switch between the mannose on the uroplakins and the mannose
in the solution. If this switch happens in time, the bacteria are not
urinated out. The adhesin is more tightly bound to HM, thus the
bacteria are urinated out before being able to bind to the
uroplakins. The tighter binding of the heptyl sugar is potentially
reducing the number of UPEC able to bind and invade the
bladder cells, and establish a robust infection. To confirm this, an
PLoS ONE | www.plosone.org

ex vivo gentamicin protection assay was performed. This allows
enumeration of both the extracellularly bound and intracellular
bacteria. There was a significant reduction in both bound and
invaded bacteria in the presence of 5 mM HM. In summary, HM
is interfering not only with binding but also with invasion of
UPEC. A 5 mM concentration of HM is needed for full inhibition
of bacterial adhesion in vivo (Figures 7 and 8), versus a 1 mM
concentration in vitro (Figure 6). In the mouse model, there is likely
some loss of the sugar due to voiding or possibly degradation in the
bladder. It is also not clear how the number and nature of
mannose receptors in the mouse bladder relate to those on the
human bladder cell line 5637. Moreover in the mouse the innate
immune responses has an influence on bacterial adhesion and
invasion.
What is clear is that the UTI89 cystitis strain binds HM, which
deters binding to the bladder cells, limiting invasion, and reducing
the level of infection. These data confirm that invasion in bladder
cells is type 1-dependent [6], as was demonstrated by the noninvasive character of FimH mannose-binding pocket mutants [53].
Several possible invasion pathways for UPECs have been
described. Direct binding of FimH to a3 and b1 integrins has
been very recently observed and has been shown to depend upon
the glycosylation of the integrins, because treatment of a3/b1
integrins with PNGaseF or EndoHf abolished all binding [33].
Bacterial invasion through glycan-mediated interactions of FimH
with integrins could also happen indirectly via cellular receptors of
differentiated bladder cells, such as CD151, CD46 and UPIa [36].

Structure, specificity and drug design
The type 1 pilus fimbrial adhesin FimH was co-crystallized with
oligomannose-3 to study in detail the interactions with this most
specific and natural glycan receptor for FimH. As expected, the
tyrosine gate plays a dominant role in the strength and specificity
of these interactions. A remarkable feature when analysing the
PHI/PSI-chology of the FimH RBD main chain are the tyrosine
residues of the tyrosine gate. Both Tyr48 and Tyr137 and even
Ile13 are on the borderline for allowed main chain conformations
of the Ramachandran plot [60]. The higher affinity of mannopentaose over mannotriose is not reflected in the oligomannose-5
versus oligomannose-3 affinities [26]. The lack of an increased
affinity of oligomannose-5 over oligomannose-3 indicates that the
choice of FimH is in both cases directed straightforwardly towards
the Mana1,3Manb1,4GlcNAcb1,4GlcNAc epitope at the nonreducing end of the D1 arm in both oligosaccharides (Figure 1).
Further substitution on the a1,6 linked mannose (Man4’) would at
least not hinder binding of oligomannose-5 via the same epitope,
as Man4’ does not interact with FimH and extends into the
solvent.
The similarity of interactions found in the crystal structures of
FimH with oligomannose-3 and butyl a-D-mannose is remarkably
high. The butyl chain follows the hydrophobic trail through the
tyrosine gate along the a1,3 and the first b1,4 glycosidic linkage to
GlcNAc2 (Figure 5A). The same trail is conservedly hydrated near
the presumable a1,3 and the first b1,4 exocyclic glycosidic linkages
(Figure 5B). Finally and as expected, the extensive hydrogen
network around the non-reducing mannose residue in the
mannose-binding pocket of FimH is fully conserved [45].
Considerable interest exists in the molecular basis for FimHmediated adhesion, being fed by long-standing observations that
blocking the FimH-receptor interaction prevents bacterial infection [21,55]. Structural insight in the basis for specificity into the
extended binding site of FimH was lacking until now, seriously
hampering and invalidating structure-based design of antiadhesive molecules using organic chemistry. Due to the great
9
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need for anti-adhesives to treat and prevent UTIs, the search was
nevertheless continued. Dendrimers of mannose-based inhibitors
were most often unable to act multivalently on E. coli, however the
monovalent moiety of the best inhibitors among those dendrimers
contain structures whose interactions can closely mimic those of
oligomannose-3, such as glycocluster 4 in the recent study by
Touaibia [61]. In these inhibitors, the a-anomeric oxygen of the
non-reducing mannose is linked to a phenyl ring, containing an
ethyn group in the para position and finalizing in a hydroxyl or
ether function. A cocrystal structure for such a complex is
unfortunately unknown, however it can be easily imagined that the
mannose would anchor in the FimH polar pocket, the a-linkage to
the phenyl group would resemble the Mana1,3Man linkage, and
the phenyl group would ideally stack with the aromatic side chain
of Tyr48. The phenyl to ethyn coupling would strengthen the van
der Waals contacts that the Manb1,4GlcNAc glycosidic linkage
makes with Tyr137 (Figure 4). The triple-bond character of the
ethyn could replace the stacking between the C4-C5 bond of
GlcNAc2 and the aromatic ring of Tyr137 (Figure 4). Finally, the
methoxy or methanol carbon atom would mimic the interaction of
C6 of GlcNAc2 with Tyr48 and Ile52, and the terminal hydroxyl
or ether oxygen may form a hydrogen bond with Thr51
(Figures 3D and 4).
In conclusion, subnanomolar inhibitors precisely mimic the kind
of interactions FimH makes with oligomannose-3, and do so in an
enhanced fashion dependent on the chemical nature of the synthetic
moieties engineered to replace all but the mannoside that enters the
monosaccharide binding pocket. The knowledge of all specific
interactions between FimH and its natural high-mannose receptor
and the possibility to relate the specificity- and affinity determining
spots on the ligand with the efficiency of synthetic inhibitors can
greatly enhance structure-based drug design against lower UTIs.

Co-crystallization of the FimH RBD with oligomannose-3
Crystallization conditions were screened at the high-throughput
crystallization facility of the EMBL in Hamburg. Crystals grew at
292K, using the vapor diffusion method with sitting drops
composed of 300 nL FimH-oligomannose-3 solution FimH at
13.6 mg/ml mixed with 2 mM oligomannose-3 in a 2:1 molar
ratio and 300 nL precipitant (Figure S1), equilibrated against a
100 ml reservoir of 1.0 M lithium sulfate, 0.1 M Tris-HCl at
pH 8.5, 0.01 M nickel (II) chloride. To optimize these conditions,
hanging drops were set up consisting of 1 ml FimH at 13.6 mg/ml
mixed with 2 mM oligomannose-3 in a 2:1 molar ratio and 1 ml of
the precipitant solution, equilibrated against 500 ml of the same
precipitant complemented with 3% glycerol. Glycerol has a
beneficial effect on crystallization by preventing showering of the
protein prior to nucleation, allowing a more controlled crystal
nucleation and growth process.

Structure determination and refinement
X-ray data have been collected to 2 Å resolution at the
European Molecular Biology Laboratory (EMBL) beam line X12
at the Deutsches Elektronen Synchrotron (DESY, Hamburg,
Germany). The crystal was flash cooled to 100K in the precipitant
solution complemented with 30% isopropanol. All data were
processed with DENZO and SCALEPACK from the HKL suite
[62]. TRUNCATE from the CCP4 suite was used to calculate
structure-factor amplitudes from the intensities. The structure has
been solved by molecular replacement with MolRep [63] using the
structure of the receptor-binding domain of FimH as the search
model (PDB entry code 1UWF) [47]. The model was refined using
rigid body refinement and the maximum likelihood function of
CNS version 1.1 [64] and Refmac 5.2.0019 [65], with 5% of the
data retained for cross-validation purposes. The initial molecular
replacement solution was submitted to simulated annealing
refinement. Successive positional and individual temperature
factor refinements were alternated with manual model adjustment
using TURBO-FRODO [66] and COOT [67] graphics.

Materials and Methods
Sugar compounds
Oligomannose-3 was custom-synthesized at the Zelinsky
Institute of Organic Chemistry (Russia). Methyl a-D-mannose
and D-mannose were purchased from Sigma-Aldrich. Mana1,3ManbOMe (S. Oscarson, to be communicated) and HM [47] have
been synthesized. Affinity measurements using surface plasmon
resonance (SPR) were performed as described [26]. Briefly, the
equilibrium dissociation constants of mannose derivatives for
FimH were determined using competition in solution for FimH
binding of the sugars with an immobilized Fab fragment from the
monoclonal antibody 1C10.

Structure analysis
A Ramachandran plot was drawn using Molprobity [68].
Baverage from the CCP4 suite [69] defined the average B-factors
of the main chain atoms of the protein and of the water molecules.
The packing contacts were analyzed using the CCP4 program
CONTACT [69], using an intermolecular cut-off distance of 4 Å.
Potential hydrogen bonds in the FimH-oligomannose-3 complex
were identified using HBPLUS [70]. Subsequently, the predicted
interactions were carefully checked with Coot [67]. Pictures have
been generated using Pymol version 0.99.

Purification of FimH
The receptor-binding domain (RBD) of the FimH protein
(residues 1 till 158 of UPEC J96) was expressed from plasmid
pMMB91 transformed into E. coli C43 (DE3) cells. C43 (DE3)
(pMMB91) E. coli cells were grown in minimal medium containing
40 mg/ml of all the amino acids, 0.4% glucose, 2 mg/ml biotin,
2 mg/ml thiamine, 2 mM MgCl2 and 25 mg/ml kanamycin at
37uC. At OD600nm = 0,6 the bacteria cells were induced with 1mM
IPTG. After overnight incubation at 37uC, cells were collected and
the periplasmic content was extracted. The receptor-binding
domain of FimH was purified by dialysing it 4h at 4uC against
20 mM Na formate pH 4 and loading it on a Mono S HR column
(Pharmacia Biotech). The protein was eluted with 20 mM Na
formate, 1M NaCl pH 4. Fractions containing the FimH receptorbinding domain were pooled and dialyzed overnight at 4uC
against 20 mM Hepes pH 8 and 150 mM NaCl, before
crystallization.
PLoS ONE | www.plosone.org

Bacterial binding in vitro to a human urothelial cell line
The E. coli strains AAEC185(pUT2002)(pMMB66) and
AAEC185(pUT2002) have been used in bladder cell binding
experiments. AAEC185 E. coli cells are fim-null mutants [72]. The
pUT2002 plasmid carries the complete fim gene cluster with the
deletion of fimH, resulting in FimH-deficient type 1 pili [72]. The
fimH gene of J96 E. coli is located on the pMMB66 plasmid [53].
Strains
AAEC185(pUT2002)
and
AAEC185(pUT2002)
(pMMB66) were grown statically in 100 ml LB for 48 hours at
37uC to induce pili production. The bacterial cells were harvested
under sterile condition by centrifugation at 3500 rpm for 20 min
(Megafuse 1.0R, Heraeus instruments) and washed two times in
phosphate buffered saline (PBS). The expression of type 1 pili was
always checked using haemagglutination [26] prior to the infection
of the bladder cells. Human bladder epithelial cell line 5637
10
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(American Type Culture Collection HTB-9) was seeded in 12-well
plates and cultured in Roswell Park Memorial Institute (RPMI)
1640 medium, supplemented with 10% fetal calf serum (FCS).
The cells were maintained 2–4 days at 37uC in a humidified
atmosphere containing 5% CO2 for confluent growth. The plate
was washed 5 times with PBS complemented with 0.5 mM MgCl2
and 1 mM CaCl2 directly before use. Each well was incubated
with 0.5 ml of 106 to 107 colony forming units (cfu) per ml in PBS.
The plates were slowly shaken for 15 minutes to allow binding of
the bacteria to the tissue cells. Five washes were performed with
PBS to remove unbound bacteria. Bladder cells were lysed by
adding 0.4 ml trypsin/EDTA for 10–15 minutes. Finally, the lysis
was stopped by the addition of 10% FCS, when all cells were
released from the plate. The input colony forming units (cfu) and
the output cfu in each well were determined by 10-fold serial
dilutions (1, 1022, 1023, 1024, 1025) in PBS and spotting 20 ml
drops on LB-agar with the appropriate antibiotics. Inhibition of
bladder cell binding was performed simultaneously as binding on
the same 12-well plate, but with the bacterial inoculum preincubated with different concentrations of mannose or HM.

efficient killing of extracellular bacteria. The bladders were washed
twice more to remove residual gentamicin and homogenized in
1 mL 0.025% triton X-100/PBS and bacterial counts were
determined by plating serial dilutions on LB agar plates.

Biofilm assay
UTI89 was grown overnight in LB broth at 37uC with shaking and
diluted 1:1000 in LB or LB with varying amounts of methyl a-Dmannose or heptyl a-D-mannose. 96-well round bottom polyvinyl
chloride plates (Falcon) were sterilized in tissue culture hood under
UV irradiation for at least 30 minutes. 100 ml of the solutions were
then added to the sterile PVC plate, 6 wells per variable. LB without
bacteria was added to 6 wells as a blank. The plate was incubated for
48 hours at room temperature, washed 3 times in PBS and allowed to
dry. 125 ml of 1% crystal violet solution was added to each well for
10 minutes. After staining, the plates were washed again in PBS 3
times and allowed to dry. The crystal violet was solubilized with
150 ml of 33% acetic acid, 100 ml was transferred to a flat bottom
plate and absorbance was read at 600 nm.

Protein Data Bank accession number

In vivo bladder binding

The coordinates and the structure factors have been submitted
to the Protein Data Bank with accession codes 2vco and r2vcosf
respectively.

All studies using mice were approved by the Animal Studies
Committee of Washington University. Eight-week-old female
C3H/HeN mice (NCI) were anesthetized and inoculated with a
50 ml suspension of ,107 UTI89 (in PBS or sugar solution) via
transurethral catheterization [12]. Prior to inoculation, the
inoculum was incubated for 20 min at 37uC with one of the
following: 1 M methyl a-D-mannose, 0.5 mM heptyl a-Dmannose, 5 mM heptyl a-D-mannose. Six hours after inoculation,
animals were euthanized, and their bladders harvested and
homogenized in 1 mL of 0.025% Triton X-100/PBS. Bacterial
titers were determined by plating serial dilutions of the
homogenates on LB agar plates. Duplicate experiments of 5 mice
each were performed.

Supporting Information
Figure S1 Crystals of the FimH receptor-binding domain in
complex with oligomannose-3. The crystals were grown by the
vapour diffusion method in 1.0 M Li2SO4, 0.1 M Tris pH 8.5,
0.01 M NiCl2, A, in sitting drop, diffracting to 2.6 {Angstrom}
resolution, and B, in hanging drop, optimized by the addition of
3% glycerol to the precipitant and diffracting to a maximum
resolution of 2.0 {Angstrom}.
Found at: doi:10.1371/journal.pone.0002040.s001 (5.22 MB TIF)
Table S1 Data collection and processing, refinement statistics
and model quality.
Found at: doi:10.1371/journal.pone.0002040.s002 (0.02 MB
DOC)

Gentamicin protection assay
UTI89 was grown overnight in LB and resuspended in PBS to
an inoculum of ,107 cfu in 50 ml. The inoculum was then
incubated for 20 min at 37uC with 5 mM methyl a-D-mannose,
0.5 mM heptyl a-D-mannose, 5 mM heptyl a-D-mannose, or
PBS. After incubation, 6–7 week old C3H/HeN mice were
inoculated via transurethral catheterization [12]. An ex vivo
gentamicin protection assay was performed as previously described
[11]. Briefly, at 1 hour post-infection, the mice were sacrificed and
bladders were dissected aseptically. Each bladder was washed 3
times with sterile PBS. The washes were collected and plated to
obtain the luminal fraction of bacteria. The bladders were then
treated with 100 mg/ml gentamicin for 90 min at 37uC. After
treatment, the supernatant was removed and titered to ensure
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